Core Framework & Diagram Why Does Cancer Relapse?
7 月 7, 20261 Min Read Why Does Cancer Metastasize?
7 月 7, 2026It was 'cured' — then five years later it came back, and it's harder to treat than before
—— Cancer relapse isn't bad luck — it's residual cancer cells that evolved for five years under immune surveillance.
I. Minimal residual disease (MRD): the invisible enemy'
The standard for 'clinical remission' in past decades has primarily relied on imaging (CT, PET-CT) and tumor markers (CEA, PSA, AFP) — methods that can detect tumor burdens around approximately 100 million cancer cells. When tumor burden falls below this threshold, all these methods show 'negative' — doctors and patients see 'remission,' but in reality hundreds of thousands to millions of cancer cells may still be lurking somewhere. This is MRD — residual cancer cells that truly exist but current clinical tests can't find, the most fundamental biological source of cancer relapse.
MRD's primary 'hiding places' fall into three categories: 'immune-privileged micro-zones' in the primary site — certain micro-zones (like hypoxic regions at the tumor center) have extremely limited chemotherapy drug penetration, cancer cells surviving in these 'sanctuaries' and waiting; distant pre-metastatic foci — a small number of cancer cells migrate via blood or lymphatics to distant organs and 'hibernate,' reactivating years to even a decade later; and circulating tumor cells (CTCs) in peripheral blood — a small number of cancer cells floating in the blood, homing and establishing at new sites when conditions are right.
The liquid biopsy (ctDNA testing) revolution is changing MRD monitoring capability. Modern ultra-sensitive ctDNA testing can detect relapse signals from blood months to even half a year before traditional imaging discovers relapse.
2. Cancer stem cells (CSC): the 'seeds' of cancer relapse
The cancer stem cell (CSC) hypothesis is one of the most important conceptual frameworks for understanding 'late relapse' and 'treatment resistance.' CSC isn't a specific cell type but a cancer cell subpopulation with special 'stem cell-like' characteristics: self-renewal capacity (can divide infinitely, producing more CSCs while also producing differentiated 'ordinary cancer cells'); multi-lineage differentiation capacity (can produce multiple cancer cell subtypes constituting tumor heterogeneity); high treatment resistance (low proliferation rate, high drug efflux pump expression, strong antioxidant capacity, efficient DNA repair); and dormancy capacity (can enter deep 'dormancy' in specific microenvironments with extremely low metabolic activity, almost insensitive to all treatments).
CSCs in tumors are usually a very small proportion (one to five percent), but their role in relapse is like tinder in a forest fire. Large-scale chemotherapy can burn down ninety-nine percent of 'ordinary cancer cells,' but if CSCs survive, they can 'rebuild' the entire tumor years later. This explains why certain cancers suddenly relapse years after 'complete remission' — not 'treatment failure' but a very small number of CSCs 'reactivated' after years of 'dormancy' by some trigger (immunosenescence, new hormonal changes, local inflammation).
3. 'Relapse windows': when is relapse risk highest?
Different cancer types' relapse time distributions have their biological patterns. Hormone receptor-positive breast cancer's 'bimodal relapse' particularly merits attention: the first relapse peak (two to five years) comes from rapid expansion of treatment-resistant subclones; while 'late relapse' after five years mainly comes from CSC dormancy activation, potentially occurring ten, fifteen, even twenty years after treatment ends. This is why for hormone receptor-positive breast cancer, guidelines recommend extending adjuvant endocrine therapy from the traditional five years to ten years — specifically targeting late relapse risk from CSC dormancy activation.
Non-small cell lung cancer's relapse peak concentrates within two years after treatment, primarily from treatment-resistant subclones and micrometastasis activation. Colorectal cancer sees seventy-five percent of relapses within three years, primarily liver micrometastasis activation — CEA and CT every three to six months for three years after surgery. Melanoma can relapse at any time including over ten years; adjuvant immune checkpoint inhibitor treatment has been proven to significantly reduce melanoma relapse risk.
4. The immune system's role in relapse
'Relative immune deficiency' triggering relapse: many patients after chemotherapy or radiation have immune systems in varying degrees of damaged states — white cell decreases, NK cell function declining, T cell exhaustion markers increasing. During this 'immune window,' MRD previously controlled by the immune system in 'equilibrium' may seize the opportunity to expand, completing the 'equilibrium → escape' transition. This is the most important immunological mechanism of immediate post-treatment relapse.
Psychological stress and relapse: multiple epidemiological studies found that cancer patients who experience major negative life events (bereavement, divorce, major career crisis) show significantly elevated relapse risk. The biological mechanism involves stress-induced adrenaline (catecholamine) secretion — catecholamines through β-adrenergic receptors directly promote tumor cell proliferation and metastasis while suppressing NK cell and CTL function. A 2016 Cancer Research animal study showed chronic stress significantly accelerated breast cancer mice's lung metastasis, while β-blockers (propranolol) partially reversed this effect — direct evidence of the 'psychological stress → immune change → cancer relapse' pathway.
5. Risk reduction strategies with evidence support
Adjuvant immunotherapy is one of currently the most evidence-supported relapse risk reduction strategies. Pembrolizumab for Stage III melanoma adjuvant treatment reduces relapse risk by approximately forty-four percent. MRD-guided individualized treatment is rapidly spreading: stopping chemotherapy after ctDNA turns negative, intensifying treatment for persistently ctDNA-positive patients — this 'MRD-guided dynamic treatment adjustment' has become standard for hematological malignancies and is rapidly being adopted for solid tumors.
Regular exercise is the most evidence-supported behavioral intervention: multiple prospective studies confirm that regular exercise in breast cancer remission periods (≥150 minutes moderate-intensity aerobic exercise per week) can reduce relapse risk by twenty to forty percent. The mechanism involves IL-6 from exercise activating NK cell migration, plus insulin/IGF-1 axis improvement. Psychological support and stress management: based on the 'stress → immunity → relapse' mechanism, standardized psychological support (cognitive behavioral therapy) has shown signals of reducing breast cancer relapse risk in some studies.
6. Post-remission lifestyle: not returning to 'before cancer'
Many cancer patients after 'clinical remission' eagerly want to 'return to before' — return to pre-illness lifestyle. This feeling is completely understandable, but from the MRD and immune surveillance perspective, 'post-remission' is actually a phase requiring even more serious attention to healthy lifestyle than before illness. Post-remission is one of the most critical periods for maintaining immune surveillance efficiency — the body still has MRD, the immune system is the only force controlling these residual lesions, and chemotherapy/radiation's damage to the immune system may still be recovering.
In this phase, every behavioral choice supporting immune system function (adequate sleep, regular exercise, not smoking, healthy diet, effective stress management) directly affects whether MRD will develop into relapse. This isn't asking patients to live in anxiety, but letting them understand: post-remission lifestyle is actively participating in one's own tumor control, not merely waiting for the next follow-up visit.
Frequently Asked Questions